In Phase A, members will acquire distinct doses and schedules of oral ABBV-744 pill to identify Risk-free dosing program. Extra individuals are going to be enrolled in the identified monotherapy dosign regimen. In Section B, members will acquire oral ruxolitinib and ABBV-744 will probably be presented as "increase-on" therapy. In https://abbv-744preclinicalstudie46790.liberty-blog.com/32173401/getting-my-abbv-744-brd4-inhibitor-clinical-efficacy-in-refractory-cancers-to-work